NXS Stock Overview
Engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Next Science Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.14 |
| 52 Week High | AU$0.50 |
| 52 Week Low | AU$0.12 |
| Beta | 1.51 |
| 11 Month Change | 3.70% |
| 3 Month Change | -39.13% |
| 1 Year Change | -49.09% |
| 33 Year Change | -88.48% |
| 5 Year Change | -93.64% |
| Change since IPO | -89.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| NXS | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -9.7% | -0.4% | 0.9% |
| 1Y | -49.1% | 13.5% | 17.7% |
Return vs Industry: NXS underperformed the Australian Medical Equipment industry which returned 14.2% over the past year.
Return vs Market: NXS underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| NXS volatility | |
|---|---|
| NXS Average Weekly Movement | 14.4% |
| Medical Equipment Industry Average Movement | 9.2% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: NXS's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: NXS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | I.V. Hall | www.nextscience.com |
Next Science Limited engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial gel that conforms to the postoperative wound; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
Next Science Limited Fundamentals Summary
| NXS fundamental statistics | |
|---|---|
| Market cap | AU$41.63m |
| Earnings (TTM) | -AU$20.71m |
| Revenue (TTM) | AU$35.75m |
1.2x
P/S Ratio-2.0x
P/E RatioIs NXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXS income statement (TTM) | |
|---|---|
| Revenue | US$23.31m |
| Cost of Revenue | US$4.93m |
| Gross Profit | US$18.37m |
| Other Expenses | US$31.87m |
| Earnings | -US$13.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.046 |
| Gross Margin | 78.83% |
| Net Profit Margin | -57.93% |
| Debt/Equity Ratio | 0% |
How did NXS perform over the long term?
See historical performance and comparison